Vitamin D linked to MS progression

Researchers from the Harvard School of Public Health measured serum concentrations of 25-hydroxyvitamin D among a total of 465 participants in 18 European countries as well as Israel and Canada who were taking part in a clinical trial originally designed to look at the impact of early versus delayed interferon beta-1b treatment in those with a first event suggestive of MS. 

The researchers found that higher levels of vitamin D in the first 12 months following this first event predicted slower progression of MS and reduced MS activity. 

The findings suggest supplements could be a simple treatment for newly diagnosed patients. 

Vitamin D levels were measured at onset of symptoms and again at six, 12 and 24 months to account for seasonal differences and to minimise the possibility that lower vitamin D levels were a consequence rather than a cause of MS progression. 

Patients were followed up for five years for clinical